Atea Pharmaceuticals (AVIR) Gains from Sales and Divestitures (2020)

Atea Pharmaceuticals (AVIR) recorded quarterly Gains from Sales and Divestitures of $20000.0 in Q4 2020.

Atea Pharmaceuticals (AVIR) Gains from Sales and Divestitures (2020) Analysis & Trends

Atea Pharmaceuticals' Gains from Sales and Divestitures history runs 1 years deep, the most recent figure standing at $20000.0 for Q4 2020.

In Q4 2020, Gains from Sales and Divestitures changed N/A year-over-year to $20000.0; the TTM figure through Dec 2020 stood at $20000.0 (changed N/A YoY), while the FY2020 annual figure was $20000.0, changed N/A from the prior year.
Gains from Sales and Divestitures was $20000.0 for Q4 2020 at Atea Pharmaceuticals.
In the past five years, Gains from Sales and Divestitures ranged from a high of $20000.0 in Q4 2020 to a low of $20000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Atea Pharmaceuticals	347.28 Mn	347.28 Mn	-

Download Data

Date	Value
Dec 31, 2020	20,000.00
Dec 31, 2020	20,000.00